C9orf72 proline-arginine dipeptide repeats disrupt the proteasome and perturb proteolytic activities

Yifan Zhang1, Sophia C K Nelson1, Ashley P Viera Ortiz2

  • 1Department of Biology, Haverford College, Haverford, Pennsylvania, USA.

Insights

Proline-arginine (polyPR) aggregates found in C9orf72-expanded ALS (C9ALS) impair cellular proteasomes. This study confirms polyPR-proteasome binding in vivo, revealing a key mechanism in C9ALS pathogenesis.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • C9orf72 hexanucleotide repeat expansion is the primary genetic cause of familial amyotrophic lateral sclerosis (ALS).
  • Aberrant translation produces dipeptide repeats (DPRs), including neurotoxic proline-arginine (polyPR).
  • Previous in vitro studies suggested polyPR impairs proteasome function.

Purpose of the Study:

  • To confirm and functionally characterize polyPR-induced proteasome impairment in C9ALS patient tissue and an in vivo model.
  • To establish the clinical relevance of polyPR-proteasome interactions in vivo.

Main Methods:

  • Confocal microscopy and immunofluorescence in human and Drosophila melanogaster brain tissues.
  • Co-immunoprecipitation assays in D. melanogaster.
  • Analysis of protein ubiquitination, lysosomal function, and rescue with a proteasomal enhancer in vivo.

Main Results:

  • PolyPR was found sequestered with proteasomes in inclusion-like bodies in both human and fly brains.
  • Direct binding of polyPR to the proteasome was confirmed via co-immunoprecipitation.
  • In vivo, proteasome impairment was evidenced by ubiquitinated protein accumulation and lysosomal dysfunction, which were reversible.

Conclusions:

  • This study provides the first clinical report of polyPR-proteasome interactions.
  • In vivo evidence demonstrates that polyPR-induced proteolytic dysfunction is a pathogenic mechanism in C9orf72-expanded ALS (C9ALS).
  • Targeting proteasome enhancement may offer a therapeutic strategy for C9ALS.

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
865
The Unfolded Protein Response01:37

The Unfolded Protein Response

The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.7K
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
782
Export of Misfolded Proteins out of the ER01:32

Export of Misfolded Proteins out of the ER

After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.6K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Protein Modifications in the RER01:26

Protein Modifications in the RER

Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
5.2K